- Home
- ZIMV vs MNPR Comparison
ZIMV vs MNPR Comparison
Compare ZIMV & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- MNPR
- Stock Information
- Founded
- ZIMV 2021
- MNPR 2014
- Country
- ZIMV United States
- MNPR United States
- Employees
- ZIMV N/A
- MNPR N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- MNPR Health Care
- Exchange
- ZIMV Nasdaq
- MNPR Nasdaq
- Market Cap
- ZIMV 262.9M
- MNPR 249.5M
- IPO Year
- ZIMV N/A
- MNPR 2019
- Fundamental
- Price
- ZIMV $9.14
- MNPR $31.73
- Analyst Decision
- ZIMV Hold
- MNPR Strong Buy
- Analyst Count
- ZIMV 2
- MNPR 5
- Target Price
- ZIMV $10.00
- MNPR $59.50
- AVG Volume (30 Days)
- ZIMV 183.4K
- MNPR 18.2K
- Earning Date
- ZIMV 05-08-2025
- MNPR 05-13-2025
- Dividend Yield
- ZIMV N/A
- MNPR N/A
- EPS Growth
- ZIMV N/A
- MNPR N/A
- EPS
- ZIMV N/A
- MNPR N/A
- Revenue
- ZIMV $443,551,000.00
- MNPR N/A
- Revenue This Year
- ZIMV $2.13
- MNPR N/A
- Revenue Next Year
- ZIMV $2.27
- MNPR N/A
- P/E Ratio
- ZIMV N/A
- MNPR N/A
- Revenue Growth
- ZIMV N/A
- MNPR N/A
- 52 Week Low
- ZIMV $8.15
- MNPR $1.72
- 52 Week High
- ZIMV $22.40
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- ZIMV 51.71
- MNPR 37.28
- Support Level
- ZIMV $8.15
- MNPR $34.02
- Resistance Level
- ZIMV $9.02
- MNPR $36.82
- Average True Range (ATR)
- ZIMV 0.34
- MNPR 3.54
- MACD
- ZIMV 0.10
- MNPR -0.71
- Stochastic Oscillator
- ZIMV 82.85
- MNPR 27.91
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.